Basel Medical Group Ltd Ordinary Shares
Here’s whether Basel Medical Group Ltd Ordinary Shares (BMGL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 39 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.62% over 10 days); weak 1-year return of -86.1%; 3-month momentum negative (-7.7%); rising volume on a downtrend (distribution, 2.96x avg). Currently 89.3% off its 52-week high. Score: -5/7.
BMGL is trading below its 200-day MA ($1.02) — a key warning sign the longer-term trend is under pressure. An RSI of 38.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -86.1% compares to +24.4% for SPY (trailed the market by 110.5%). The current 89.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.